Biotricity

Biotricity R&D per Employee

Delisted

The R&D Spending per Employee of Biotricity (BTCY) as of Oct 31, 2026 is 119,761.11 USD. In the previous year, R&D Spending per Employee was 142,877.78 USD — a change of -16.18% (lower).

R&D per Employee

119,761.11USD

YoY

-16.18%

Last updated:

R&D Spending per Employee of Biotricity is 2025 119,761.11 USD. R&D Spending per Employee of Biotricity was 2024 142,877.78 USD. It decreases by -16.18% lower compared to the previous year.

The Biotricity R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
97,777.78 USD
Jan 1, 2019
71,111.11 USD
Jan 1, 2020
75,555.56 USD
Jan 1, 2021
114,444.44 USD
Jan 1, 2022
152,222.22 USD
Jan 1, 2023
179,444.44 USD
Jan 1, 2024
142,877.78 USD
Jan 1, 2025
119,761.11 USD
The Biotricity R&D per Employee history
YEARR&D per EmployeeYoY
119,761.11USD-16.18%
142,877.78USD-20.38%
179,444.44USD+17.88%
152,222.22USD+33.01%
114,444.44USD+51.47%
75,555.56USD+6.25%
71,111.11USD-27.27%
97,777.78USD+54.39%
63,333.33USD+4.59%
60,555.56USD-4.39%
63,333.33USD+37.35%
46,111.11USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotricity Stock analysis

What does Biotricity do? Biotricity, Inc. generates revenue through its remote biometric monitoring solutions, primarily targeting healthcare providers and patients with chronic conditions. The company offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases and coronary heart diseases, detect arrhythmias via ambulatory monitoring, and provide real-time remote mobile cardiac telemetry diagnostics. Additionally, Biotricity sells biolife, a health and lifestyle solution for individuals that monitors heart-rhythm, ECG, respiration, calories, temperature, and physical activity through a dedicated device. Healthcare institutions and patients seeking chronic condition management and lifestyle improvement are the primary buyers of these products. The firm's revenue streams are derived from the sale of bioflux systems to medical professionals for diagnostic and post-diagnostic use, while biolife targets individual consumers for personal health monitoring. Bioflux is utilized by physicians for real-time ECG data transmission and arrhythmia detection, and biolife is marketed directly to individuals for comprehensive health tracking. Both products are sold through direct sales channels to their respective target segments. Biotricity's business model relies on the dual focus of medical diagnostics and consumer health solutions. The company's products are designed to serve two distinct market segments: healthcare providers using bioflux for clinical diagnostics and patients using biolife for personal health management. The remote monitoring capabilities of both systems facilitate ongoing health data collection and analysis, supporting chronic disease management and lifestyle enhancement. Biotricity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotricity stock

R&D Spending per Employee of Biotricity is 119,761.11 USD in 2025.

R&D Spending per Employee of Biotricity changed from 142,877.78 USD to 119,761.11 USD, representing a -16.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Biotricity since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Biotricity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biotricity

All Key Metrics — Biotricity